| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 01/02/2003 | US20030004187 Method for preventing dyskinesias |
| 01/02/2003 | US20030004186 Anticoagulants; cardiovascular disorders; central nervous system disorders |
| 01/02/2003 | US20030004185 Viricides, organ transplants, antiarthritic agents |
| 01/02/2003 | US20030004180 Central nervous system disorders; psychological disorders |
| 01/02/2003 | US20030004178 Synergistic mixture |
| 01/02/2003 | US20030004177 Abuse-resistant opioid dosage form |
| 01/02/2003 | US20030004176 Mixture of analgesic and addition reducting compound of a gamma-aminobutyric acid |
| 01/02/2003 | US20030004174 Antiinflammatory agents, anticancer agents, antihistamines, central nervous system disorders |
| 01/02/2003 | US20030004172 Cardiovascular disorders, osteoporosis, multiple sclerosis, antiarthritic agents |
| 01/02/2003 | US20030004169 Modulators of dopamine neurotransmission |
| 01/02/2003 | US20030004166 Novel triazine compounds useful as sorbitol dehydrogenase inhibitors |
| 01/02/2003 | US20030004164 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004163 Antiinflammatory agents; headaches; antiarthritic agents |
| 01/02/2003 | US20030004161 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004155 Pharmaceutical compositions |
| 01/02/2003 | US20030004154 New crystal forms of oxcarbazepine and processes for their preparation |
| 01/02/2003 | US20030004153 Novel heteroaryl-diazabicycloalkanes |
| 01/02/2003 | US20030004151 Cyclic derivatives as modulators of chemokine receptor activity |
| 01/02/2003 | US20030004147 5-beta-sapogenin and pseudosapogenin derivatives and their use in the treatment of dementia |
| 01/02/2003 | US20030004144 Anticancer agents; skin disorders |
| 01/02/2003 | US20030004139 Antidiabetic agents |
| 01/02/2003 | US20030004137 Muscle relaxants, controlling immunology, strokes, antidiabetic agents |
| 01/02/2003 | US20030004129 Formulations of adenosine a1 agonists |
| 01/02/2003 | US20030004128 Formulatios of adenosine a1 agonists |
| 01/02/2003 | US20030004127 Formulations of adenosine a1 agonists |
| 01/02/2003 | US20030004126 Formulations of adenosine A1 agonists |
| 01/02/2003 | US20030004107 Method of preventing cell death using segments of neural thread proteins |
| 01/02/2003 | US20030004106 Interleukin-1 receptor antagonist-related molecules and uses thereof |
| 01/02/2003 | US20030004099 The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
| 01/02/2003 | US20030003574 Multipotent stem cells from peripheral tissues and uses thereof |
| 01/02/2003 | US20030003545 Nucleotide sequences coding polypeptide for use in the treatment of immunological defects |
| 01/02/2003 | US20030003532 Novel nucleic acid sequences encoding human slit-, megf-, and roundabout-like polypeptides |
| 01/02/2003 | US20030003516 Therapeutic and diagnostic uses of antibody specificity profiles |
| 01/02/2003 | US20030003462 Novel human interleukin-like proteins and polynucleotides encoding them |
| 01/02/2003 | US20030003453 DNA molecule encoding a variant paraoxonase and uses thereof |
| 01/02/2003 | US20030003445 Method of preventing cell death using antibodies to neural thread proteins |
| 01/02/2003 | US20030003168 Enriched in at least two of the phytochemicals selected from the group consisting of isoflavones, lignans, saponins, catechins and phenolic acids. |
| 01/02/2003 | US20030003163 For restoration and maintenance of gingival and periodontal health; antiplaque/antitar agents; mouthwash |
| 01/02/2003 | US20030003158 Pharmaceutical composition for preventing and treating erectile impotence using purified sumsoo extract |
| 01/02/2003 | US20030003150 System for osmotic delivery of pharmaceutically active agents |
| 01/02/2003 | US20030003141 Contacting a blood vessel wall cell with an A beta 40 inhibitor, such that cerebral amyloid angiopathy is inhibited |
| 01/02/2003 | US20030003130 Compositions for regulating desire for smoking |
| 01/02/2003 | US20030003082 Use of poly-Glu,Tyr and T cells treated therewith for neuroprotective therapy |
| 01/02/2003 | US20030000518 Delivery of nonsteroidal antiinflammatory drugs through an inhalation route |
| 01/02/2003 | EP1271153A2 Collapsin response mediator protein-1 as tumor metastasis marker |
| 01/02/2003 | EP1270588A1 Novel collagen-like protein clac, precursor thereof and genes encoding the same |
| 01/02/2003 | EP1270585A1 Peptide derivative |
| 01/02/2003 | EP1270574A1 Caffeine complexes with improved flavour, process for their preparation and their use |
| 01/02/2003 | EP1270573A1 Xanthine and phenazone acesulfam-H complexes with improved taste, process for their preparation and their use |
| 01/02/2003 | EP1270570A1 Amide compounds and use thereof |
| 01/02/2003 | EP1270569A1 Substituted tryptophan derivatives |
| 01/02/2003 | EP1270568A1 1-methyl-4-(3-ethoxy-9h-thioxanthene-ylidene)-piperidine and its use as 5-HT2B and/or H1 antagonist |
| 01/02/2003 | EP1270567A1 Pyrazoline derivatives or tetrahydropyridazine derivatives and medicinal use thereof |
| 01/02/2003 | EP1270559A1 Novel imidazole derivatives with anti-inflammatory activity |
| 01/02/2003 | EP1270545A1 Process for producing amine derivatives |
| 01/02/2003 | EP1270044A2 Wound healing biomarkers |
| 01/02/2003 | EP1270007A2 Microemulsions for the transdermal administration of apomorphine, for the treatment of Parkinson's disease |
| 01/02/2003 | EP1270002A2 Pharmaceutical compositions for preventing problem behaviour of companion animals |
| 01/02/2003 | EP1269201A1 Alpha 7 nicotinic receptor screening assays |
| 01/02/2003 | EP1269196A1 Method of screening for inhibitors of osteopontin |
| 01/02/2003 | EP1268835A1 Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for the treatment of neurological disorders |
| 01/02/2003 | EP1268820A2 Estrogen-regulated myo-inositol phosphate synthase: compositions and methods of use |
| 01/02/2003 | EP1268817A1 Human pyruvate dehydrogenese phosphatase |
| 01/02/2003 | EP1268802A2 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 01/02/2003 | EP1268792A2 Wnt-7b-like polypeptides and nucleic acids encoding same |
| 01/02/2003 | EP1268785A2 Gtp-binding protein gamma-12 subunit |
| 01/02/2003 | EP1268781A2 G12l, a gene associated with the thermal response |
| 01/02/2003 | EP1268775A1 The high bone mass gene of 11q13.3 |
| 01/02/2003 | EP1268773A1 Immune system-related polynucleotides, polypeptides, and antibodies |
| 01/02/2003 | EP1268772A2 Peptide and nucleic acid coding therefor for the detection, diagnosis and therapy of diseases of the nervous system |
| 01/02/2003 | EP1268768A2 Targeted chromosomal genomic alterations with modified single stranded oligonucleotides |
| 01/02/2003 | EP1268756A2 Methods and compositions for modulating integrin-mediated cell-cell interactions |
| 01/02/2003 | EP1268554A2 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| 01/02/2003 | EP1268546A2 G protein-coupled receptors |
| 01/02/2003 | EP1268543A2 Methods and materials relating to stem cell growth factor-like polypeptides and polynucleotides |
| 01/02/2003 | EP1268510A2 Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides |
| 01/02/2003 | EP1268503A1 O-glucosylated benzamide sglt2 inhibitors and method |
| 01/02/2003 | EP1268502A1 O-aryl glucoside sglt2 inhibitors and method |
| 01/02/2003 | EP1268495A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 01/02/2003 | EP1268494A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 01/02/2003 | EP1268489A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-a]pyrimidines as antidepressant agents |
| 01/02/2003 | EP1268487A1 Tricyclic protein kinase inhibitors |
| 01/02/2003 | EP1268484A1 Condensed imidazoles as histamine h3 receptor ligands |
| 01/02/2003 | EP1268483A1 Condensed imidazoles as histamine h3 receptor ligands |
| 01/02/2003 | EP1268480A1 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors |
| 01/02/2003 | EP1268478A2 Phenyl-substituted imidazopyridines |
| 01/02/2003 | EP1268474A2 Substituted 1,3-thiazole compounds, their production and use |
| 01/02/2003 | EP1268471A1 N-heterocyclic derivatives as nos inhibitors |
| 01/02/2003 | EP1268466A1 Decahydro-isoquinolines |
| 01/02/2003 | EP1268465A1 Triarylimidazole derivatives as cytokine inhibitors |
| 01/02/2003 | EP1268455A2 Piperazine derivatives |
| 01/02/2003 | EP1268454A1 Succinoylamino heterocycles as inhibitors of a-beta protein production |
| 01/02/2003 | EP1268453A1 Estrogen agonist/antagonist metabolites |
| 01/02/2003 | EP1268450A1 Lactams substituted by cyclic succinates as inhibitors of a-beta protein production |
| 01/02/2003 | EP1268437A1 Inhibitors of protein kinases |
| 01/02/2003 | EP1268435A1 4,5-dihydro-1h-pyrazole derivatives having cb 1-antagonistic activity |
| 01/02/2003 | EP1268434A1 Cyclic lactams as inhibitors of a-beta protein production |
| 01/02/2003 | EP1268433A1 Cyclic lactams as inhibitors of a-beta-protein production |
| 01/02/2003 | EP1268427A1 Aminopyridines and their use as anticonvulsants and sodium channel blockers |
| 01/02/2003 | EP1268425A2 Carbamate caspase inhibitors and uses thereof |